Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Inclusion criteria: * A new diagnosis of T1D based on the ADA criteria within 6 months of randomization. * Male and female between the ages of 18 and 40 * Mentally stable and able to comply with the procedures of the study protocol * Positivity for at least one T1D-associated autoantibody, such as GAD, IA-2 or ZnT8 autoantibodies * At screening, patients must have residual β cell function with a stimulated peak C-peptide \>0.2 nmol/l during a 2 hour MMTT * Must be willing to comply with "intensive diabetes management" (\* See diabetes management at MUSC below) as directed by the participant's clinician with the goal of maintaining blood glucose as close to normal as possible * Subject must be willing to comply with the schedule of study visits and protocol requirements * Subject with normal laboratory values of: White blood cell counts: between 4,500 to 11,000 per microliter; Platelet counts: 140,000 to 450,000 platelets per microliter of blood; Serum creatinine range is 0.6-1.3 mg/dL, Hepatic function: ALT 5 to 55 units per liter (U/L), AST 5 to 48 U/L. Exclusion criteria: * Evidence of retinopathy at baseline based on ophthalmologic examination or medical record review. * Body Mass Index \< 14 or \>35 * Presence of malignancy * Subject has abnormally high lipid levels that exceeds \> 3 times the upper limit of normal for LDL cholesterol or triglycerides * Subject has blood pressure greater than 160 mmHg systolic or 100 mmHg diastolic at time of consent * Subject is being…